Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease

Background The International Study Group on Pancreatic Surgery recommends upfront surgery for resectable pancreatic cancer or borderline resectable‐venous (BR‐V) disease and neoadjuvant therapy (NAT) among those with arterial involvement (BR‐A or locally advanced, LA). Though neoadjuvant therapy (NA...

Full description

Saved in:
Bibliographic Details
Published in:ANZ journal of surgery 2021-07, Vol.91 (7-8), p.1549-1557
Main Authors: Kamarajah, Sivesh K., Chatzizacharias, Nikolaos, Hodson, James, Marcon, Francesca, Kalisvaart, Marit, Punia, Pankaj, Ting Ma, Yuk, Dasari, Bobby, Marudanayagam, Ravi, Sutcliffe, Robert P., Muiesan, Paolo, Mirza, Darius F., Isaac, John, Roberts, Keith J.
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Locally advanced
neoadjuvant
Pancreatic cancer
Patients
Surgery
Survival
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The International Study Group on Pancreatic Surgery recommends upfront surgery for resectable pancreatic cancer or borderline resectable‐venous (BR‐V) disease and neoadjuvant therapy (NAT) among those with arterial involvement (BR‐A or locally advanced, LA). Though neoadjuvant therapy (NAT) is a promising strategy, outcomes are rarely reported on intention‐to‐treat (ITT) basis. This study presents ITT outcomes where pathways to surgery were in line with International Study Group on Pancreatic Surgery guidelines. Methods Patients recommended for potentially curative treatment with PDAC between 2012 and 2017 (n = 345) were classified as resectable, BR‐A/BR‐V or LA, according to NCCN criteria. The primary outcome was overall survival. Secondary outcomes were resection rates, positive margins and toxicity among patients receiving NAT. Results At surgery, the resection rates were 78% (172/221), 65% (35/54) and 54% (21/39) for those with resectable, BR‐V and BR‐A/LA disease, respectively (P 
ISSN:1445-1433
1445-2197
DOI:10.1111/ans.16643